Free Trial

Achilles B. Kintiroglou Sells 571 Shares of AdvanSix (NYSE:ASIX) Stock

AdvanSix logo with Basic Materials background

AdvanSix (NYSE:ASIX - Get Free Report) SVP Achilles B. Kintiroglou sold 571 shares of the business's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $24.85, for a total transaction of $14,189.35. Following the completion of the sale, the senior vice president directly owned 31,984 shares in the company, valued at approximately $794,802.40. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AdvanSix Trading Up 1.2%

Shares of ASIX traded up $0.29 during trading hours on Wednesday, hitting $25.09. 173,418 shares of the stock were exchanged, compared to its average volume of 153,058. AdvanSix has a fifty-two week low of $18.44 and a fifty-two week high of $33.00. The business has a 50-day moving average of $23.38 and a 200-day moving average of $25.46. The firm has a market capitalization of $672.66 million, a P/E ratio of 8.04 and a beta of 1.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.19 and a quick ratio of 0.56.

AdvanSix Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, May 27th. Stockholders of record on Tuesday, May 13th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 2.55%. The ex-dividend date of this dividend was Tuesday, May 13th. AdvanSix's dividend payout ratio (DPR) is presently 20.51%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ASIX. JPMorgan Chase & Co. grew its stake in AdvanSix by 5.5% during the fourth quarter. JPMorgan Chase & Co. now owns 110,289 shares of the company's stock worth $3,142,000 after purchasing an additional 5,705 shares during the period. American Century Companies Inc. boosted its holdings in shares of AdvanSix by 15.8% during the 4th quarter. American Century Companies Inc. now owns 740,028 shares of the company's stock worth $21,083,000 after buying an additional 100,841 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of AdvanSix during the 4th quarter worth approximately $663,000. Envestnet Asset Management Inc. acquired a new stake in shares of AdvanSix during the 4th quarter worth approximately $228,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of AdvanSix by 29.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,279 shares of the company's stock valued at $2,031,000 after acquiring an additional 16,078 shares in the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on the company. Piper Sandler set a $32.00 target price on AdvanSix in a report on Monday, May 19th. Wall Street Zen raised AdvanSix from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 31st. Finally, UBS Group set a $35.00 target price on AdvanSix in a report on Tuesday, March 18th.

View Our Latest Analysis on ASIX

AdvanSix Company Profile

(Get Free Report)

AdvanSix Inc engages in the manufacture and sale of polymer resins in the United States and internationally. It offers Nylon 6, a polymer resin, which is a synthetic material used to produce fibers, filaments, engineered plastics, and films. The company also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone that are used in the production of adhesives, paints, coatings, solvents, herbicides, and engineered plastic resins, as well as other intermediate chemicals, including phenol, monoisopropylamine, dipropylamine, monoallylamine, alpha-methylstyrene, cyclohexanone, methyl ethyl ketoxime, acetaldehyde oxime, 2-pentanone oxime, cyclohexanol, sulfuric acid, ammonia, and carbon dioxide.

Further Reading

Insider Buying and Selling by Quarter for AdvanSix (NYSE:ASIX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AdvanSix Right Now?

Before you consider AdvanSix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AdvanSix wasn't on the list.

While AdvanSix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025
3 Defense Stocks Under $10 With Massive Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines